Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Blinded CDCA 250 mg TID
Mirum Pharmaceuticals International B.V.
CTX
1 trial -
Brelovitug (BJT-778)
Mirum Pharmaceuticals International B.V.
Chronic Hepatitis D
1 trial -
Brelovitug 300 mg
Mirum Pharmaceuticals International B.V.
Chronic Hepatitis D Infection
3 trials -
Cholic Acid
Mirum Pharmaceuticals International B.V.
Bile Acid Synthesis Defect
1 trial -
Cholic Acids
Mirum Pharmaceuticals International B.V.
Infantile Refsum's Disease
1 trial -
Cholic acid
Mirum Pharmaceuticals International B.V.
Inborn Errors of Bile Acid Synthesis
1 trial -
Maralixibat
Mirum Pharmaceuticals International B.V.
Progressive Familial Intrahepatic Cholestasis (PFIC)
3 trials -
Maralixibat
Mirum Pharmaceuticals International B.V.
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
1 trial -
LUM001
Mirum Pharmaceuticals International B.V.
Primary Biliary Cirrhosis
1 trial -
LUM001
Mirum Pharmaceuticals International B.V.
Alagille Syndrome
2 trials -
LUM001
Mirum Pharmaceuticals International B.V.
PBC
1 trial -
LUM001
Mirum Pharmaceuticals International B.V.
Primary Sclerosing Cholangitis (PSC)
1 trial -
LUM001 (Maralixibat)
Mirum Pharmaceuticals International B.V.
Progressive Familial Intrahepatic Cholestasis (PFIC)
1 trial -
LUM001 (Maralixibat)
Mirum Pharmaceuticals International B.V.
Alagille Syndrome
3 trials -
Low dose of MRM-3379
Mirum Pharmaceuticals International B.V.
Fragile X Syndrome
1 trial -
Maralixibat
Mirum Pharmaceuticals International B.V.
Intrahepatic Cholestasis of Pregnancy
1 trial -
Maralixibat
Mirum Pharmaceuticals International B.V.
Progressive Familial Intrahepatic Cholestasis
1 trial -
Maralixibat
Mirum Pharmaceuticals International B.V.
Biliary Atresia
1 trial -
Maralixibat
Mirum Pharmaceuticals International B.V.
Cholestatic Liver Disease
1 trial -
SHP626
Mirum Pharmaceuticals International B.V.
Non-Alcoholic Steatohepatitis
3 trials -
Volixibat
Mirum Pharmaceuticals International B.V.
Intrahepatic Cholestasis of Pregnancy
1 trial -
Volixibat
Mirum Pharmaceuticals International B.V.
Primary Sclerosing Cholangitis
1 trial -
Volixibat
Mirum Pharmaceuticals International B.V.
Primary Biliary Cholangitis
1 trial -
Placebo
Mirum Pharmaceuticals International B.V.
Healthy Volunteers
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources